10-Q: Plus Therapeutics Reports Increased Q1 Losses Amidst Key Clinical Progress and Nasdaq Compliance Challenges

Plus Therapeutics, a radiotherapeutics company, reported a significant increase in net loss for Q1 2025, alongside progress in its REYOBIQ clinical trials and ongoing efforts to address multiple Nasdaq listing deficiencies.

Summary

• Plus Therapeutics reported a net loss of $17.4 million for the three months ended March 31, 2025, a substantial increase from $3.3 million in the same period of 2024.
• The company's accumulated deficit reached $510.9 million as of March 31, 2025.
• Net cash used in operating activities increased to $6.2 million for Q1 2025, up from $4.5 million in Q1 2024.
• The company successfully closed a private placement on March 7, 2025, raising approximately $15.0 million in gross proceeds through the issuance of common stock, prefunded warrants, and Series A and Series B warrants.
• This financing helped the company regain compliance with Nasdaq's Minimum Stockholders Equity Requirement on March 7, 2025, though it remains under a Mandatory Panel Monitor until March 7, 2026.
• However, Plus Therapeutics received new notices from Nasdaq on May 16, 2025, for failing to meet the minimum $1.00 bid price requirement, and on May 21, 2025, for delaying its Q1 2025 10-Q filing.
• Clinical trial updates include the completion of Phase 1 for ReSPECT-LM (leptomeningeal metastases) with a recommended Phase 2 dose identified and one patient achieving a complete response, and ongoing Phase 2 enrollment for ReSPECT-GBM (recurrent glioblastoma) targeting full enrollment by end of 2025.
• The company also submitted an IND for its ReSPECT-PBC (pediatric brain cancer) clinical trial in Q4 2024, supported by a $3.0 million DoD award.
• The CNSide Platform, a cerebrospinal fluid cancer diagnostic portfolio acquired in April 2024, is planned for re-introduction to the U.S. market in Q2 2025, with prior trial data showing enhanced diagnostic sensitivity.
• The company moved its headquarters to Houston, Texas, in March 2025 and appointed Mr. Kyle Guse as a new independent director and Chairman of the Audit Committee on April 18, 2025.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to a significant increase in net loss and cash burn, coupled with multiple ongoing Nasdaq compliance issues (bid price and delayed filing) that pose a serious delisting risk. While a recent capital raise provided a temporary liquidity boost and resolved one Nasdaq issue, the 'going concern' warning and highly dilutive nature of the financing overshadow the positive clinical trial progress.

Positives

• Successfully raised approximately $15.0 million in gross proceeds from a March 2025 private placement, significantly improving cash and working capital positions.
• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on March 7, 2025.
• Completed Phase 1 of the ReSPECT-LM clinical trial, identifying a recommended Phase 2 dose and observing a complete response (eradication of tumor cells in CSF) in one patient at that dose level.
• Received a $3.0 million Department of Defense (DoD) award to support the planned expansion of the pediatric brain cancer clinical trial (ReSPECT-PBC).
• FDA conditionally accepted the proprietary name REYOBIQ for its lead radiotherapeutic candidate.
• FDA granted orphan drug designation to REYOBIQ for the treatment of leptomeningeal metastases in patients with breast cancer (November 2023) and lung cancer (March 2025).
• Interim Phase 2 data for ReSPECT-GBM showed a favorable safety profile and a statistically significant reduction in tumor volume rate change in tumors receiving a sufficient absorbed dose.
• The acquired CNSide Platform demonstrated enhanced diagnostic sensitivity (80% vs. 29% for cytology) and influenced treatment decisions in over 90% of LM cases in the FORESEE trial.
• Entered into a manufacturing services agreement with SpectronRx for drug product development and manufacturing, with an initial proposal expected in H2 2025.

Negatives

• Reported a significantly increased net loss of $17.4 million for Q1 2025, compared to $3.3 million for Q1 2024.
• Net cash used in operating activities increased to $6.2 million in Q1 2025 from $4.5 million in Q1 2024, indicating higher cash burn.
• Received a Nasdaq notice on May 16, 2025, for non-compliance with the minimum bid price requirement ($1.00 per share) for 30 consecutive business days.
• Received a Nasdaq notice on May 21, 2025, for delay in filing the Quarterly Report on Form 10-Q for Q1 2025.
• The company's accumulated deficit grew to $510.9 million as of March 31, 2025.
• Grant revenue decreased to $1.1 million in Q1 2025 from $1.7 million in Q1 2024.
• General and administrative expenses increased by $0.6 million in Q1 2025 compared to Q1 2024, primarily due to higher compensation and legal/professional fees.
• The company explicitly states that factors raise substantial doubt about its ability to continue as a going concern.
• The March 2025 Private Placement involved highly dilutive warrants (Series A and Series B) that could significantly increase the number of common shares issuable upon exercise.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to ongoing net losses and cash burn.
• Risk of delisting from Nasdaq due to failure to comply with the Minimum Bid Requirement ($1.00 per share) by November 12, 2025, or potential future non-compliance with the Minimum Stockholders Equity Requirement.
• Risk of delisting from Nasdaq due to the delayed filing of the Quarterly Report on Form 10-Q, with a deadline to submit a compliance plan by July 21, 2025.
• The highly dilutive nature of the March 2025 Series A and Series B Warrants, which could lead to a significant increase in outstanding common stock and potential Nasdaq public interest concerns, possibly resulting in a trading halt or delisting.
• Inability to raise additional capital in the future, which would materially and adversely impact operations and ability to satisfy obligations.
• The early stage of product candidates and therapies, with inherent uncertainties relating to clinical trials.
• Risks associated with market conditions, product performance, potential litigation, and competition within the radiotherapeutics and oncological medicine fields.
• The company is subject to a Mandatory Panel Monitor by Nasdaq until March 7, 2026, meaning any future non-compliance with the Minimum Stockholders Equity Requirement would lead directly to a delist determination without a cure period.

Future Outlook

The company anticipates beginning enrollment for a ReSPECT-LM Multi-Dose trial in the first half of 2025 and for its Phase 1 ReSPECT-PBC clinical trial in 2025. Full enrollment for Phase 2 of the ReSPECT-GBM trial is targeted by the end of 2025, with a data read-out expected by the same time. The CNSide Cerebrospinal Fluid Tumor Cell Enumeration test is planned to be re-introduced to the U.S. market starting in the second quarter of 2025. The company expects aggregate research and development expenses and general and administrative expenditures to largely remain consistent during the remainder of 2025 compared to the corresponding comparable periods in 2024. The company continues to seek additional capital to fund future clinical development programs and operations.

Management Comments

• Management believes that the alignment with the FDA regarding cGMP guidance for REYOBIQ will be consistent across all clinical development programs (GBM, LM, PBC) as the product is identical.
• The company intends to monitor the closing bid price of its common stock and may consider implementing available options, including a reverse stock split, to regain compliance with the Nasdaq Minimum Bid Requirement.
• Management acknowledges the ongoing need to raise additional cash from outside sources to fund future clinical development programs and other operations, stating that inability to do so would have a material adverse impact.

Industry Context

Plus Therapeutics operates in the highly competitive and challenging field of central nervous system (CNS) cancers, which includes aggressive diseases like glioblastoma (GBM) and leptomeningeal metastases (LM) with very poor prognoses and significant unmet medical needs. The company's focus on targeted radiotherapeutics, utilizing novel drug formulations and medical devices, aims to overcome limitations of traditional radiation therapies by delivering higher, more precise radiation doses directly to tumors while minimizing exposure to healthy tissues. The acquisition of the CNSide diagnostic platform positions the company to offer both therapeutic and diagnostic solutions, aligning with the growing trend of precision medicine in oncology. The company's pipeline addresses critical areas where current treatments offer only marginal survival benefits.

Comparison to Industry Standards

• REYOBIQ aims to deliver radiation doses up to 20 times greater than commonly used external beam radiation therapy (EBRT), while sparing normal tissue and the brain from radiation exposure, a key advantage over traditional methods.
• Unlike EBRT, which requires continuous treatment for four to six weeks, REYOBIQ is designed for a single, short, in-patient hospital visit, offering a significant convenience benefit for patients.
• REYOBIQ's ability to be visualized in real-time during administration potentially offers clinicians better control over radiation dosing and distribution compared to less targeted approaches.
• The CNSide Test demonstrated enhanced sensitivity in detecting tumor cells (80%) versus gold standard cerebrospinal fluid cytology (29%) in patients with LM, indicating a significant improvement in diagnostic capability within the industry.

Management Changes

Corporate Governance

Related Party Transactions

• The May 2024 Private Placement included participation from certain of the company's directors and executive officers (Company Insiders).

Stakeholder Impact

• Shareholders face significant dilution risk from the large number of shares issuable upon exercise of the March 2025 Series A and Series B Warrants.
• Shareholders are exposed to substantial risk of Nasdaq delisting due to ongoing bid price non-compliance and delayed filing, which could severely impact stock liquidity and market price.
• Employees and management are impacted by the company's ongoing need for capital and the 'going concern' warning, which could affect job security and future operations.
• Patients may benefit from the continued progress in clinical trials for REYOBIQ in various CNS cancers and the planned re-introduction of the CNSide diagnostic platform, offering potential new treatment and diagnostic options.
• Creditors and investors in the recent private placement are subject to the terms of the warrants and the company's ability to continue operations and generate future revenue.

Next Steps

• Regain compliance with Nasdaq's Minimum Bid Requirement by November 12, 2025, potentially through a reverse stock split.
• Submit an updated plan to Nasdaq by July 21, 2025, to regain compliance with the timely filing rule for the 10-Q.
• Begin enrollment for a ReSPECT-LM Multi-Dose trial in the first half of 2025.
• Begin enrollment for the Phase 1 ReSPECT-PBC clinical trial in 2025.
• Achieve full enrollment in Phase 2 of the ReSPECT-GBM trial by the end of 2025, with a data read-out expected by the same time.
• Re-introduce the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test to the U.S. market starting in the second quarter of 2025.
• Negotiate a commercial supply agreement with SpectronRx upon six months' written notice before the company's first commercial manufacturing needs.

Key Dates

Recommendation

Keywords

Radiotherapeutics, Oncology, Glioblastoma, Leptomeningeal Metastases, Pediatric Brain Cancer, REYOBIQ, CNSide Platform, SEC Filing, 10-Q, Nasdaq Compliance, Clinical Trials, Biotechnology, Pharmaceutical, Cancer Treatment, Drug Development, Medical Device